Alnylam announces appointment of elliott sigal, m.d., ph.d., to board of directors

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny) the leading rnai therapeutics company, announced today the appointment of elliott sigal, m.d., ph.d., to its board of directors. dr. sigal brings decades of senior leadership and board experience at biopharmaceutical companies. he served as chief scientific officer and president of r&d for bristol-myers squibb (bms) and as a director on the company's board. during his tenure at bms, he was instrumental in buildi
ALNY Ratings Summary
ALNY Quant Ranking